Profit, I know you said Friday , but could tomorrow be the dày ?
The filing said either the lower of the average of the 3 days or the closing price of August 21st . Am I reading this wrong ? So if price increases tomorrow the adjustment price is already set lower for the average of the three days , so the 21st only matters to keep the average lower. Let's just say that is price closes around . 40 tomorrow the average is still only around .20 as opposed the the .40 !
I read this somewhere before too .. Oh wait it was right here !!! Am I in that group ?
Phew when I read the headline I almost thought this was the SEAL of approval to buy . Good thing I dug deeper !!
Maybe he was talking about different stages of the disease . How everyone is different . I do t know ... Are these different components different options ? Or is this a single treatment ?
Important Development and Collaborations
I believe we should have three components for the treatment of Wolfram syndrome.
1. Delay the progression of the disease with existing FDA-approved drugs.
This is our current major focus, and we have a rising candidate. We are looking for a simple way to assess the efficacy of this drug in patients and are trying to collect blood samples from patients and their siblings. In parallel, we are also looking for a new group of drugs that can delay the progression of the disease with a company. All of these drugs seem to be related to cellular calcium homeostasis.
2. Enhance the viability of eye cells, brain cells, and pancreatic beta cells.
In Wolfram syndrome, brain cells, eye cells, and beta cells in the pancreas are sensitive to cell stress and susceptible to cell death due to the mutations in the WFS1 gene. We are developing a method to make brain cells, eye cells, and pancreatic beta cells, more resistant to cell stress. We have identified an interesting hormone-like molecule produced in our body called MANF. MANF can make our cells more resistant to cell stress-mediated cell death. We are trying to establish a collaboration with a pharmaceutical company to develop a drug based on our findings.
3. Replace damaged tissues using patients' skin cells.
As I mentioned in my previous blogs, we have created induced pluripotent stem cells (iPS cells) using skin cells from patients. We are creating brain cells and eye cells using these iPS cells. These cells have been useful to dissect out the mechanisms of the disease and test the efficacy of candidate drugs. We are also replacing a pathogenic WFS1 gene part with a healthy WFS1 gene part in these cells. In the future, we will use these cells for replacing damaged tissues.
I think July is going to be a very interesting time for Ambs . Maybe your prediction could be by July 31.
GC Blog------The Company has had 3 posters accepted for presentation (analytical performance, LP001 retrospective 7 year patient record clinical performance data, and LP002 2014 clinical performance) at the Alzheimer’s Association International Conference (AAIC) this July in Copenhagen under the direction of Dr. Louis Kirby and Paul Jorgensen. Our primary focus will be the data of the LP001 retrospective patient record study currently underway with our collaborator’s facility at Banner Sun Health Research Institute in Phoenix, AZ. We believe this data will be the most compelling for Key Opinion Leaders (KOLs) and pharmaceutical companies, our target market for the initial launch of LymPro, as this will provide longitudinal data regarding LymPro’s performance and diagnostic integrity.
The Company is contemplating withholding the release of the LP002 clinical performance data until our #C4CT Concussion Awareness Summit, which will focus on TBI-induced Alzheimer’s disease, at the United Nations on July 31st. This would allow the Company to maintain a laser focus on potential customers at AAIC using the most compelling LP001 retrospective data and allowing the information to be thoroughly digested by the scientific community and analysts. In doing so, the LP002 data would be shared with family offices and a world-expert panel of TBI and Alzheimer’s researchers who would then be in a position to sign on as sites for the validation study required for CLIA registration. We will update the market on this option in the weeks ahead.
Mk I am probably just as guilty for responding the way I did I missed that post . But non the less I just can't figure some things out . If I was new here and seen your original post it would have intrigued me to look more into manf . After all you did state a reason to be long . And if he really is intent to move the stock higher and I seen his response that yours was a soft bash I would have thought you said something negative . And maybe not trusted you . So that confuses me . But maybe it's not for me to figure out . Good luck to you !!! And all .
Going ... I was going to agree with you mk was only stating an opinion !
And to me that opinion was positive . For the life of me I can't understand what a " soft bash " is , when you state this is a reason to be long ! Don't you only need one reason to be long ? Can't that be looked at as a soft pump . I also use to like risks informative posts . But at times he does come across as almost desperate . What does it matter what ones opinions are ... If you love the company buy long and you will be rewarded . I think it does weaken and taint what I use to respect as good info. Cause now it makes me think is he just desperate . Now on the other hand you stood behind mk post as I was and he came back with a slam of risks family !! An eye for an eye I suppose ! But serves no purpose here! No wonder we cant break .11 haha
What I like is the wording . He seems so confident ! Reading all his tweets and blogs that this is one step or hurdle he has been waiting for !! Great news !!!
"I am excited by a new collaboration with Amarantus Bioscience to develop A REVOLUTIONARY THERAPY FOR WOLFRAM SYNDROME, the most difficult form of blindness and diabetes. We will use MANF protein derived from human brain to achieve this goal. "
Speller... I did not take that as a soft bash !!! After all
It has been something the company itself has talked about!!!
So it is something that should be discussed here. Also GC
Has stated in one of his blogs "It is important to note, the Company will not contemplate a reverse split at current price levels thereby mitigating that risk in the near-term. I also agree with banker should it not happen this way it will be a controlled split. Ambs is an interesting company , while 800 mil sounds like a lot . The areas they are working in are huge. I believe it can be done without a split ! But that is just my opinion ! Glta
I believe there could be a share buy back . They would need
Revenue but a lot of it .. Cause with these young companies
They would need the cash for studies they were working on.
Unless they were to get a partnership where they received a lot of upfront money.
Also where the partner funded some of the research . Could be possible !!!
In regards to the tweet GC made is sound like information
Or data was going to be released very soon ! That may have
Caused a little excitement .
But then the blog almost made it sound as if things weren't going to
Start happening till mid to late July ! I realize that is still soon
But to many of the impatient investors/ flippers here not son enough.
Then the blog also talked about the manf collaborations which if I were a flipper would
Scare me cause that data sounds like it could come at any time !
Whatever your strategy , glta
Too funny ... Talks about GC pumping and the stock being a shipwreck
But goes on to say they will buy later !!!